Welcome to our dedicated page for China Sxt Pharmaceuticals SEC filings (Ticker: SXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The China SXT Pharmaceuticals, Inc. (SXTC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. China SXT is a specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces (TCMPs) and Traditional Chinese Medicine Homologous Supplements (TCMHS), with operations based in Taizhou, Jiangsu, China and revenue generated from the People’s Republic of China, as described in its public documents.
China SXT files annual reports on Form 20-F and current reports on Form 6-K, along with registration statements such as Form F-3 for securities offerings. For example, a Form 6-K details the company’s 2025 special meeting of shareholders and the approval of a dual-class share structure, creating Class B Ordinary Shares with fifty votes per share and re-designating existing ordinary shares as Class A Ordinary Shares. Other filings reference the use of a shelf registration statement on Form F-3 for a registered direct offering of Class A ordinary shares (or pre-funded warrants in lieu thereof).
Through this page, users can review how China SXT reports changes in its capital structure, including share consolidations and the adoption of amended and restated memorandum and articles of association, as well as documents related to special shareholder meetings. Real-time updates from the SEC’s EDGAR system are combined with AI-powered summaries that explain the key points of lengthy filings, helping readers understand the implications of forms such as 20-F, 6-K, and F-3 without reading every page.
Investors and researchers can use the SXTC filings page to examine the company’s governance arrangements, voting rights, listing-related disclosures, and details of registered offerings, all as presented in its official SEC submissions.
China SXT Pharmaceuticals completed a registered direct offering involving 12,000,000 Class A ordinary shares and pre-funded warrants to purchase 54,666,666 Class A ordinary shares. The company received approximately $9,110,000 in net proceeds after placement and other offering expenses and plans to use the cash for general corporate purposes. The pre-funded warrants are exercisable at $0.001 per share, may be exercised on a cash or cashless basis, and include a 9.99% beneficial ownership cap so a holder cannot exceed that ownership level through exercise. Univest Securities, LLC acted as exclusive placement agent and was paid a 7.0% cash fee on gross proceeds, a 0.5% non-accountable expense allowance, and up to $100,000 of out-of-pocket costs.
China SXT Pharmaceuticals is raising capital through a registered offering of 12,000,000 Class A Ordinary Shares at $0.15 per share, along with Pre-Funded Warrants to purchase up to 54,666,666 Class A Ordinary Shares at a purchase price of $0.149 and exercise price of $0.001 per share. The company is also registering 54,666,666 Class A Ordinary Shares issuable upon exercise of these Pre-Funded Warrants.
Total gross proceeds are expected to be about $9.95 million, with proceeds before expenses of about $9.25 million and an estimated net of approximately $9.11 million, to be used primarily for working capital and general corporate purposes. Shares outstanding would increase from 116,027,226 to 182,693,892 Class A Ordinary Shares if all Pre-Funded Warrants are exercised.
The company is a British Virgin Islands holding company operating in China through subsidiaries and a variable interest entity, and highlights significant regulatory and structural risks related to PRC oversight, its VIE arrangements, and potential U.S. trading limitations under the Holding Foreign Companies Accountable Act.
China SXT Pharmaceuticals filed a Form F-3 shelf registration to offer and sell up to $600,000,000 of Class A Ordinary Shares, debt securities, warrants, rights, and units, to be offered from time to time after effectiveness via methods described in future prospectus supplements.
Its Class A Ordinary Shares trade on Nasdaq as “SXTC.” On November 7, 2025, the share price was $1.3704. As of November 10, 2025, non‑affiliate holdings were 116,027,226 shares, implying a public float of approximately $159,003,711 under General Instruction I.B.1. The company states the aggregate offering price under this prospectus will not exceed $600,000,000, and if public float falls below $75 million, sales in any 12‑month period will not exceed one‑third of public float as calculated under I.B.5. During the prior 12 months, it sold approximately $29,200,000 pursuant to I.B.5.
The company intends to use net proceeds described in applicable supplements for project development, business growth, working capital, and general corporate purposes, and may use a portion for acquisitions or investments.
Singapore investor Ching Choon Hwa has filed a Schedule 13G disclosing passive ownership of 9,803,920 Class A ordinary shares of China SXT Pharmaceuticals (SXTC). The position represents 8.45 % of the company’s 116.0 million total votes outstanding as of 29 Jul 2025. The filing indicates sole voting and dispositive power over the entire stake, with no shared control and no group affiliation. The investor certifies the shares were not acquired to influence control of the issuer. Because the threshold for a 13G filing is 5 %, this disclosure makes Ching Choon Hwa one of SXTC’s largest known individual shareholders, signaling added liquidity and a potential vote bloc but no stated activist intent. No financial performance data, purchase price, or acquisition timeline is provided.
FAQ
What is the current stock price of China Sxt Pharmaceuticals (SXTC)?
What is the market cap of China Sxt Pharmaceuticals (SXTC)?
